View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Carole Braudeau
  • Carole Braudeau

Morning Crédit 17/12/2025

Nouvelles rumeurs spéculatives sur le capital de Rexel (La Lettre)|S&P relève le rating corporate de Grifols de B+ à BB-/stable|

 PRESS RELEASE

Novo Nordisk phase 2 trial with amycretin reports significant weight l...

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeksAmycretin demonstrated statistically significant reductions in HbA1c with up to 89.1% achieving HbA1c levels below 7%Amycretin appeared to have a safe and well-tolerated profile consistent with incretin and amylin-based therapies Bagsværd, Denmark, 25 November 2025 – Novo Nordisk today announced positive headline results from a phase 2 clinical trial with amycretin in people with type 2 diabetes. Th...

Carole Braudeau
  • Carole Braudeau

Credit Morning 11/25/2025

Bertrand Franchise : 11.5% growth in Q3 2025 EBITDA, offsetting the decline in H1 2025|Zegona : satisfactory results in H1 2026, agreement to sell 40% of Fiberpass to AXA IM|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 25/11/2025

Bertrand Franchise : EBITDA en hausse +11.5% au T3 25, rattrapant la baisse du S1 25|Zegona : résultats satisfaisants au S1 2026, accord pour la cession de 40% de Fiberpass à AXA IM|

Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistic...

Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease. The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared to placebo on top of standard of care. The decision to pursue an Alzheimer’s disease indication with semaglutide w...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch